Compare · LNAI vs NVO
LNAI vs NVO
Side-by-side comparison of Lunai Bioworks Inc. (LNAI) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LNAI and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 17045.0x LNAI ($10.7M).
- Over the past year, LNAI is down 92.0% and NVO is down 44.1% - NVO leads by 47.9 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 4 for LNAI).
- NVO has more recent analyst coverage (25 ratings vs 0 for LNAI).
- Company
- Lunai Bioworks Inc.
- Novo Nordisk A/S
- Price
- $2.31-11.15%
- $42.19+2.89%
- Market cap
- $10.7M
- $183.15B
- 1M return
- -11.80%
- -8.44%
- 1Y return
- -91.98%
- -44.09%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 4
- 8
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LNAI
- Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration
- Federal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common Stock
- Lunai Bioworks Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT
- SEC Form 10-Q filed by Lunai Bioworks Inc.
- Lunai Bioworks Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research
- Dickinson Wright and Fox Rothschild Join Forces to File Lawsuit Against 'John Doe' 'Naked' Short-Sellers of Lunai Common Stock
- Amendment: Lunai Bioworks Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Submission of Matters to a Vote of Security Holders
- Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care